 announced  that it has entered into a collaboration with Roche Diagnostics GmbH in Penzberg, Germany. Under the agreement KINAXO's phosphoproteomics technology 

 will be applied to support the identification of biomarkers related to new treatment approaches based on therapeutic antibodies currently under development at Roche. Financial details of the agreement were not disclosed.
  
  PhosphoScout® is a global, quantitative phosphoproteomics service tailored to dissect cellular signal transduction pathways and their response to drug treatment. The technology is based on proprietary mass spectrometry methods, which enable the unbiased analysis of 15,000 phosphorylation sites in a single experiment. 

"Cellular signal transmission in eukaryotic cells is mainly regulated by the reversible phosphorylation of proteins. Therefore, differential analysis of the complete cellular phosphoproteome upon drug treatment provides highly informative insights into the modes of action of targeted cancer drugs, " commented Dr. Klaus Godl, KINAXO’s CSO.
  